Clinical Research Directory

The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK

Sponsor: The Queen Elizabeth Hospital

Summary

The goal of this observational study is to learn about the long-term effects of GLP1 agonists (weight loss jab, including Mounjaro) in patients with Bardet-Biedl Syndrome (BBS) who take GLP1 agonists to treat high body weight. The main question: Do GLP1 agonists effectively and safely lower body weight in patients with BBS when taken long-term, compared to patients not on these medications? The investigators look at the change (%) in weight during the observational periods.

Official title: GLP1 Agonists Once Weekly for the Treatment of Obesity in Patients With Bardet-Biedl Syndrome (BBS)

Key Details

Conditions

Locations (1)